Myeloproliferative neoplasm screening: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
Screening for myeloproliferative neoplasm by quantitative cell-based ''[[JAK2|JAK2V617F]]'' mutation assays may be helpful among patients with [[erythrocytosis]], [[thrombocytosis]], splanchnic vein thrombosis, and unexplained BCR-ABL1-negative [[granulocytosis]].<ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | Screening for myeloproliferative neoplasm by quantitative cell-based ''[[JAK2|JAK2V617F]]'' mutation assays may be helpful among patients with [[erythrocytosis]], [[thrombocytosis]], splanchnic vein thrombosis, and unexplained BCR-ABL1-negative [[granulocytosis]].<ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | ||
==Screening== | ==Screening== | ||
Screening for myeloproliferative neoplasm by quantitative cell-based ''JAK2V617F'' mutation assays may be helpful among patients with the following:<ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | Screening for myeloproliferative neoplasm by quantitative cell-based ''[[JAK2|JAK2V617F]]'' mutation assays may be helpful among patients with the following:<ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | ||
*[[Erythrocytosis]] | *[[Erythrocytosis]] | ||
*[[Thrombocytosis]] | *[[Thrombocytosis]] |
Revision as of 21:57, 22 October 2015
Myeloproliferative Neoplasm Microchapters |
Differentiating myeloproliferative neoplasm from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Myeloproliferative neoplasm screening On the Web |
American Roentgen Ray Society Images of Myeloproliferative neoplasm screening |
Directions to Hospitals Treating Myeloproliferative neoplasm |
Risk calculators and risk factors for Myeloproliferative neoplasm screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Screening for myeloproliferative neoplasm by quantitative cell-based JAK2V617F mutation assays may be helpful among patients with erythrocytosis, thrombocytosis, splanchnic vein thrombosis, and unexplained BCR-ABL1-negative granulocytosis.[1]
Screening
Screening for myeloproliferative neoplasm by quantitative cell-based JAK2V617F mutation assays may be helpful among patients with the following:[1]
- Erythrocytosis
- Thrombocytosis
- Splanchnic vein thrombosis
- Unexplained BCR-ABL1-negative granulocytosis
References
- ↑ 1.0 1.1 Tefferi A, Noel P, Hanson CA (2011). "Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology". J Mol Diagn. 13 (5): 461–6. doi:10.1016/j.jmoldx.2011.05.007. PMC 3157620. PMID 21723416.